SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-041673
Filing Date
2021-08-05
Accepted
2021-08-05 16:47:34
Documents
63
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-10q_20210630.htm   iXBRL 10-Q 2738427
2 EX-31.1 ntla-ex311_10.htm EX-31.1 21086
3 EX-31.2 ntla-ex312_11.htm EX-31.2 21102
4 EX-32.1 ntla-ex321_8.htm EX-32.1 6269
  Complete submission text file 0001564590-21-041673.txt   9695314

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ntla-20210630.xsd EX-101.SCH 45828
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20210630_cal.xml EX-101.CAL 32665
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20210630_def.xml EX-101.DEF 172260
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20210630_lab.xml EX-101.LAB 369298
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20210630_pre.xml EX-101.PRE 293103
10 EXTRACTED XBRL INSTANCE DOCUMENT ntla-10q_20210630_htm.xml XML 2242618
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 211149093
SIC: 2835 In Vitro & In Vivo Diagnostic Substances